about
Gene therapy in Parkinson's disease: rationale and current statusLaunching invasive, first-in-human trials against Parkinson's disease: ethical considerationsParkinson's disease gene therapy: success by design meets failure by efficacyGDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson diseaseNeuroregeneration in neurodegenerative disorders.Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.Potential future neuroprotective therapies for neurodegenerative disorders and stroke.Naringin: a protector of the nigrostriatal dopaminergic projection.Neurotrophic factor GDNF promotes survival of salivary stem cellsNeurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.Neurite outgrowth from PC12 cells is enhanced by an inhibitor of mechanical channels.Effects of naringin, a flavanone glycoside in grapefruits and citrus fruits, on the nigrostriatal dopaminergic projection in the adult brainMesenchymal stem cells for the treatment of neurodegenerative disease.Endogenous repair by the activation of cell survival signalling cascades during the early stages of rat Parkinsonism.Mammalian target of rapamycin complex 1 as an inducer of neurotrophic factors in dopaminergic neurons.Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian ratsRoles of Rheb(S16H) in substantia nigra pars compacta dopaminergic neurons in vivoSuberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damageMethodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.Resveratrol Produces Neurotrophic Effects on Cultured Dopaminergic Neurons through Prompting Astroglial BDNF and GDNF Release.Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease.Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation.alpha-Synuclein: a therapeutic target for Parkinson's disease?Protection against Parkinson's disease progression: clinical experience.Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease.Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in MiceWhat's in the pipeline for the treatment of Parkinson's disease?Direct, quantitative, and noninvasive imaging of the transport of active agents through intact brain with positron emission tomography.Emerging technologies in the delivery of erythropoietin for therapeutics.Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro.The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.An update on gene therapy in Parkinson's disease.Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease.Post 6-OHDA lesion exposure to stress affects neurotrophic factor expression and aggravates motor impairment.Protection of Cultured Dopamine Neurons from MPP(+) Requires a Combination of Neurotrophic Factors.Differential behavioral outcomes following neonatal versus fetal human retinal pigment epithelial cell striatal implants in parkinsonian rats.Induction of GDNF and BDNF by hRheb(S16H) transduction of SNpc neurons: neuroprotective mechanisms of hRheb(S16H) in a model of Parkinson's disease.Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNFTherapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice.
P2860
Q22241423-01271DAA-C511-494C-A704-F97B993B36D7Q24289526-A4F3403A-BF87-48B0-9AF7-CCDBF3913061Q26851325-B9DD232B-B9C1-4AB7-9186-04F2C555B7F4Q28083626-8F397317-459D-4963-9083-CED2908A8404Q31020342-9D7CD926-1E38-47C2-8D7E-DDEEE372244EQ33562727-14188C9A-73C5-4FD5-93E4-183FA6A0638CQ33687436-7C214BB9-F5CC-498F-9825-9AC90A85850CQ33787324-B14DC7F8-FD42-4C98-9B77-7BD5912EF407Q33944235-363E605B-F8B7-4B64-B448-41EFB808F336Q33958289-E718A558-4A4D-4B5D-9005-AD7C4E9E0E90Q34039452-3470CE2B-96AD-46CE-BCD3-13DB6F917D70Q34067418-7BB8B9C5-79AF-4B42-8A3B-C6FF47DAF411Q34319584-67905719-2303-4710-9516-478A633712CBQ34473474-4ABBE484-F7D2-46E0-8663-A5FDEA2BED59Q34516390-C831F408-FF6F-4DCE-A588-D5DE1E134D87Q35046986-E195E517-5E7D-4F42-9701-6AC6550C9A73Q35089226-20AD3D96-AC18-4D1F-906A-06F56D5214B0Q35180062-A20D5A01-A9AF-4B48-896E-0A0F934DDF63Q35708210-50AFB944-002F-4EED-9F1E-9FF5AC0C4A44Q35847142-CB5751DB-5DC1-4AA1-9FFE-3EC13D3C80C5Q36477181-26C90F6B-C791-43FF-97A0-9EDE42BD94ACQ36617859-32F6EC0D-6995-4BB1-974A-3C3B8689A181Q36848206-69509596-5469-4D07-8846-8CB5859ABB50Q37070916-23A3E835-CDB7-44A1-9132-99B52636CB74Q37131239-CE5C117F-BC64-43CB-9E1F-BEA7C3DA3C94Q37298364-810E1C16-476D-49FB-BD68-68700A7703EBQ37334985-C8514D52-8D8C-4EC7-9BE5-2DA3B57FBA16Q37352050-ECB6AC93-2338-4D4F-A42A-AEF621FA5760Q37617002-3194DD21-A510-4CB5-806E-8FE026D1FBF5Q37646523-7A072A09-1ADC-438C-A4DF-FF67A002FBDCQ37706984-897DAEA7-3E55-49F5-B8A8-1B6BF454A352Q37820210-C444A8F2-67F6-44B9-8CE0-557615381A1EQ37863587-BD9AFE18-A3DA-4300-8DAC-7F195FDFDB18Q38241183-81F935C0-C015-4437-9C14-D6FA47047B52Q38711427-547CEACE-0E35-4A0A-9E3A-ABC32B1F9A57Q38776707-CEF944BE-CD72-4E7F-A903-BC37BFC8A420Q38979736-9E600E26-4778-444B-AA56-B405F380185CQ38991795-B44FBAB2-D5E2-44DC-8BD4-E45B57E39A91Q39216202-2B80BE50-6C37-43C5-9DC9-C63CC74774BFQ39257825-CC09E90D-4468-495A-9513-AE291028C98C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of Parkinson's disease with trophic factors.
@en
Treatment of Parkinson's disease with trophic factors.
@nl
type
label
Treatment of Parkinson's disease with trophic factors.
@en
Treatment of Parkinson's disease with trophic factors.
@nl
prefLabel
Treatment of Parkinson's disease with trophic factors.
@en
Treatment of Parkinson's disease with trophic factors.
@nl
P2860
P1433
P1476
Treatment of Parkinson's disease with trophic factors.
@en
P2093
Amie L Peterson
P2860
P2888
P304
P356
10.1016/J.NURT.2008.02.003
P50
P577
2008-04-01T00:00:00Z
P5875
P6179
1052291159